SABS
SAB Biotherapeutics·NASDAQ
--
--(--)
--
--(--)
4.46 / 10
Netural
Technically, SABS scores 4.46/10 with a neutral rating. Adverse signals such as long upper shadows and RSI overbought outweigh the constructive long lower shadow, indicating short-term volatility and an unclear directional bias.
Analysis Checks(1/3)
Long Upper Shadow
Score3.37/10
Win Rate48.72%
Hist. Signals78
Avg Return1.12%
Score3.37/10
Win Rate48.72%
Hist. Signals78
Avg Return1.12%
RSI Overbought
Score3.45/10
Win Rate43.75%
Hist. Signals16
Avg Return1.84%
Score3.45/10
Win Rate43.75%
Hist. Signals16
Avg Return1.84%
Long Lower Shadow
Score6.57/10
Win Rate54.26%
Hist. Signals94
Avg Return1.87%
Score6.57/10
Win Rate54.26%
Hist. Signals94
Avg Return1.87%
Long Upper Shadow
Score3.37/10
Win Rate48.72%
Hist. Signals78
Avg Return1.12%
Score3.37/10
Win Rate48.72%
Hist. Signals78
Avg Return1.12%
Long Lower Shadow
Score6.57/10
Win Rate54.26%
Hist. Signals94
Avg Return1.87%
Score6.57/10
Win Rate54.26%
Hist. Signals94
Avg Return1.87%
RSI Overbought
Score3.45/10
Win Rate43.75%
Hist. Signals16
Avg Return1.84%
Score3.45/10
Win Rate43.75%
Hist. Signals16
Avg Return1.84%
Technical Analysis of SABS?
- SABS presents a Netural setup with a Technical Score of 4.46/10. Key technical indicators highlight an RSI of 53.46 and a MACD of -0.03, with the trend anchored by the 50-Day SMA at 3.94. Traders should monitor key support at 3.84 and resistance at 4.24.
